Nomura predicts that Kangfang Bio will turn from loss to profit in the second half of the year and raises the target price to HKD 120.64.

robot
Abstract generation in progress

Jin10 data reported on July 18 that Nomura published a report predicting that CanSino Biologics (09926.HK) will have a mid-term revenue increase of 42% year-on-year to 1.45 billion RMB, which is 3% lower than market expectations. The bank expects sales of COVAXIN and Ad5-nCoV to accelerate, with mid-term revenues of 800 million and 600 million RMB, respectively. The mid-term operating expenses are expected to be 1.3 billion RMB, with an overall mid-term net loss attributable to shareholders of 8 million RMB, close to break-even, compared to losses of 239 million and 276 million RMB in the first and second halves of last year, respectively. The bank forecasts that the company's revenue in the second half will be 1.9 billion RMB, driven by the sales of COVAXIN and Ad5-nCoV, with a predicted net profit of 271 million RMB in the second half. The bank has lowered its revenue forecast for the company this year by 9.6%, based on a downward revision of the sales and collaboration revenue estimates for Anika, while the full-year net profit forecast has been raised by 97.2%, based on higher gross margin assumptions. The target price for CanSino Biologics has been raised from 99.66 HKD to 120.64 HKD, maintaining a neutral rating.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)